Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Soleno Therapeutics’ disclosures can feel like decoding a clinical protocol: hundreds of pages on DCCR trial data, cash runway projections, and orphan-drug risks. Stock Titan turns that complexity into clarity. Our AI-powered summaries surface what matters—so you can stop skimming footnotes and start understanding.
Need to track a sudden 8-K about Phase 3 results or the latest Soleno Therapeutics quarter-end 10-Q? We post filings the moment they hit EDGAR and translate biotech jargon into plain English. Curious about Soleno Therapeutics insider trading Form 4 transactions? Real-time Form 4 dashboards reveal when executives buy more shares ahead of an FDA meeting. Wondering where DCCR R&D spend shows up? Our annotated Soleno Therapeutics annual report 10-K simplified highlights the exact line items.
Here’s how professionals use the page:
- Compare quarterly trial costs across 10-Qs without diving into accounting tables.
- Set alerts for Soleno Therapeutics executive stock transactions Form 4 before material announcements.
- Quick-read AI insights that explain each Soleno Therapeutics 8-K material event, from NDA submissions to Fast-Track designations.
Every form type is covered—10-K, 10-Q, 8-K, S-3, DEF 14A proxy statement executive compensation, and more. Whether you’re performing a Soleno Therapeutics earnings report filing analysis or simply understanding Soleno Therapeutics SEC documents with AI, you’ll find the data, context, and confidence you need—all in one place and always up to date.
Soleno Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,001,350 shares of Soleno common stock as of June 30, 2025. That holding represents 1.99% of the class. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that the positions were acquired and are held in the ordinary course of business, not to influence control.
Janus Henderson Group plc reports beneficial ownership of 5,308,009 shares of Soleno Therapeutics, Inc. (CUSIP 834203309), representing approximately 10.5% of the outstanding common stock as of the report. The filing shows shared voting and dispositive power over those shares and discloses a related holding by JHIUS of 5,241,409 shares (10.4%). The report lists the transaction date requiring the filing as 06/30/2025 and is signed on behalf of Janus Henderson on 08/14/2025.
The registrant certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing includes a power-of-attorney dated December 9, 2022, authorizing named officers to execute ownership reports on the company's behalf.
Soleno Therapeutics reported that Avoro Capital Advisors LLC and Behzad Aghazadeh beneficially own 2,050,000 shares of common stock, equal to 4.1% of the outstanding class based on 50,393,931 shares. Avoro holds the position on behalf of Avoro Life Sciences Fund LLC and Dr. Aghazadeh serves as portfolio manager and controlling person of Avoro. The filing states the shares were acquired solely for investment purposes and that the reporting persons have sole voting and sole dispositive power over the reported shares. The statement indicates the position is below a 5% threshold and is not held to change or influence control of the issuer.
Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,958,294 shares of Soleno Therapeutics common stock, representing 7.4% of the class based on 53,145,009 shares outstanding as of August 1, 2025. The reporting persons state they have sole voting and sole dispositive power over those shares and that the shares are held of record by the fund.
The filing is a Schedule 13G amendment and includes a certification that the securities were not acquired to change or influence control of the issuer, indicating the reporting persons characterize the position as passive.
Adage Capital Management, L.P., together with reporting persons Robert Atchinson and Phillip Gross, disclose beneficial ownership of 3,575,964 shares of Soleno Therapeutics common stock, representing 7.10% of the outstanding shares (based on 50,393,931 shares outstanding as reported in the company filings). The holdings are shown as shared voting power and shared dispositive power; no sole voting or sole dispositive power is reported.
The filing is a Schedule 13G/A and includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Soleno Therapeutics (SLNO)?
What is the market cap of Soleno Therapeutics (SLNO)?
